Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) tinted gains of +3.37% (+0.32 points) to US$9.81. The volume of 0.08 Million shares climbed down over an trading activity of 116.38 Million shares. EPS ratio determined by looking at last 12 month figures is -2.56. Over the same time span, the stock marked US$17.64 as its best level and the lowest price reached was US$7.42. The corporation has a market cap of US$282.04 Million.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -51.3 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 71.6 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 1.67. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Surface Oncology, Inc. (NASDAQ:SURF) is worth US$374.79 Million and has recently risen 3.36% to US$13.84. The latest exchange of 0.15 Million shares is below its average trading activity of 514.41 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$15.19 while the mean 12-month price target for the shares is US$0.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0, and a price to sales ratio of 29.28. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 16.5%, it carries an earnings per share ratio of -1.72.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.5.